2010
Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study
Krishnamurti L, Goel R, Castro O, Barst R, Rosenzweig E, Sachdev V, Machado R, Gibbs S, Little J, Schraufnagel D, Girgis R, Morris C, Badesch D, Lanzkron S, Goldsmith J, Gordeuk V, Kato G, Gladwin M, Hassell K. Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood 2010, 116: 2658. DOI: 10.1182/blood.v116.21.2658.2658.Peer-Reviewed Original ResearchTricuspid regurgitant velocityAcute pain crisisSickle cell diseasePain crisisChronic painExercise capacityIndependent predictorsClinical trialsCell diseaseAcute sickle cell pain crisisSickle cell pain crisisMultivariable logistic regression analysisSickle cellsAcute pain ratingsHypertension clinical trialsTrials of sildenafilDouble-blind placeboEmergency department visitsGroup of patientsMinute walk distanceWeeks of treatmentNon-drug therapyFuture clinical trialsSignificant lower odds ratioLogistic regression analysisLack of Difference In Co-Morbidities Associated with Deep Venous Thrombosis In Patients Undergoing Total Knee Replacement
Viswanathan P, Tiwari U, Krishnamurti L. Lack of Difference In Co-Morbidities Associated with Deep Venous Thrombosis In Patients Undergoing Total Knee Replacement. Blood 2010, 116: 2578. DOI: 10.1182/blood.v116.21.2578.2578.Peer-Reviewed Original ResearchDVT/pulmonary embolismDeep vein thrombosisTotal knee replacementICD-9-CM codesPulmonary embolismDeep venous thrombosisHealth care utilizationNational Inpatient SampleVein thrombosisKnee replacementVenous thrombosisCare utilizationTotal kneeHip replacementPostoperative deep vein thrombosisPostoperative pulmonary embolismGroup of patientsICD-9 codesLength of stayAge 18 yearsPatient safety practicesPost-operative occurrenceKnee replacement recipientsHealth care costsSecondary diagnosis fields
2008
Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L, Kharbanda S, Biernacki M, Zhang W, Baker K, Wagner J, Wu C. Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2008, 14: 1270-1278. PMID: 18940682, DOI: 10.1016/j.bbmt.2008.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellChildCyclosporineFemaleGraft SurvivalGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsLiving DonorsMaleMycophenolic AcidMyeloablative AgonistsSiblingsTransplantation ChimeraTransplantation ConditioningTransplantation, HomologousConceptsHematopoietic stem cell transplantationSickle cell diseaseRIC regimenCell transplantationCell diseaseEfficacy of HSCTHigh-risk sickle cell diseaseReduced-Intensity Hematopoietic Cell TransplantationAllogeneic hematopoietic stem cell transplantationReduced-intensity conditioning regimensEquine antithymocyte globulinHost disease (GVHD) prophylaxisTotal lymphoid irradiationAcceptable therapeutic optionHematopoietic cell transplantationGroup of patientsStem cell transplantationAntithymocyte globulinLymphoid irradiationConditioning regimenMycophenolate mofetilConditioning regimensDisease prophylaxisDonor engraftmentTherapeutic options
2005
Matched Sibling Donor Hematopoietic Cell Transplantation for Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Can Lead To Stable Long Term Engraftment.
Krishnamurti L, Wu C, Baker K, Wagner J. Matched Sibling Donor Hematopoietic Cell Transplantation for Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Can Lead To Stable Long Term Engraftment. Blood 2005, 106: 3172. DOI: 10.1182/blood.v106.11.3172.3172.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseDaily x 5 daysIntensity conditioning regimenCell diseaseConditioning regimenDay 100Stable long-term engraftmentLong-term engraftmentRIC regimenClinical characteristicsCell transplantationDay 180Term engraftmentHigh-risk sickle cell diseaseDonor hematopoietic cell transplantationLineage-specific chimerism analysisPeripheral blood genomic DNARegimen-Related ToxicitiesAnti-thymocyte globulinGroup of patientsChronic graftDonor erythropoiesisGVHD prophylaxisHost disease